Skip to content
Clinical Trials – home
GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica
Sponsor

GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica

Italy Viale Antonio Gramsci 14, 43126 Parma, Italy

About the sponsor

Research activity is concentrated in aggressive thoracic cancers, including small cell lung cancer, extensive-stage extrapulmonary small cell carcinoma, and pulmonary large-cell neuroendocrine carcinoma. The funded studies also address treatment approaches in malignant pleural mesothelioma, with attention to disease control and post-surgical outcomes.

  • Small cell lung cancer
  • Extrapulmonary small cell carcinoma
  • Large-cell neuroendocrine carcinoma
  • Malignant pleural mesothelioma

These programmes focus on immunotherapy-based and platinum-based treatment strategies in advanced thoracic disease.

About Specializations

GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica runs clinical trials in conditions such as Rectal cancer, Pleural mesothelioma malignant, Small cell lung cancer, Small cell lung cancer extensive stage, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

8 clinical trials

Rectal cancer

Recruiting

Study of XELOX chemotherapy with or without dostarlimab after chemoradiation in patients with locally advanced rectal cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica

Study on Atezolizumab for Patients with Malignant Pleural Mesothelioma After Surgery

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica

Study of Atezolizumab and Chemotherapy for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica

Study on Durvalumab with Carboplatin or Cisplatin and Etoposide for First-Line Treatment in Patients with Extensive Stage Extrapulmonary Small Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica

Study of Cemiplimab, Platinum and Gemcitabine in Treatment‑Naïve Patients with Advanced Squamous Non‑Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Cemiplimab
  • Sponsor:GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica

Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma After Second-Line Platinum-Based Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Avelumab
  • Sponsor:GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica

Study on Alectinib for Patients with ALK+ Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Alectinib
  • Sponsor:GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica

Study of durvalumab, carboplatin and etoposide combination therapy for patients with metastatic large-cell neuroendocrine lung cancer who have not received previous treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:GOIRC Gruppo Oncologico Italiano Di Ricerca Clinica

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.